The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
39929370
DOI
10.1016/j.pnpbp.2025.111285
PII: S0278-5846(25)00039-9
Knihovny.cz E-zdroje
- Klíčová slova
- Methoxphenidine, Open field, Pharmacokinetics, Systemic toxicity, Wistar rats,
- MeSH
- chování zvířat * účinky léků MeSH
- cyklohexanony * farmakokinetika MeSH
- cyklohexylaminy * farmakokinetika toxicita farmakologie MeSH
- krysa rodu Rattus MeSH
- lokomoce účinky léků MeSH
- mozek účinky léků metabolismus patologie MeSH
- pohybová aktivita účinky léků MeSH
- potkani Wistar MeSH
- prepulsní inhibice účinky léků MeSH
- psychotropní léky * farmakokinetika farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone MeSH Prohlížeč
- cyklohexanony * MeSH
- cyklohexylaminy * MeSH
- psychotropní léky * MeSH
Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration: pharmacokinetics in the brain and serum; behaviour (open field and prepulse inhibition), systemic toxicity (lethal dose; LD 50), and histopathology changes in parenchymal organs of Wistar rats. MXP rapidly crossed the blood-brain barrier, reaching peak median concentrations in both serum and brain 30 min post-administration, followed by an elimination phase with a half-life of 2.15 h. Locomotor activity in the open field test displayed a dose-response effect at low to moderate doses (10-20 mg/kg MXP). At higher doses (40 mg/kg), locomotor activity decreased. All doses of MXP significantly disrupted prepulse inhibition and the effect was present during the onset of its action as well as 60 min after treatment. Additionally, MXP demonstrated moderate acute toxicity, with an estimated LD50 of 500 mg/kg when administered subcutaneously. In summary, MXP exhibited a profile similar to typical dissociative anesthetics, producing stimulant and anxiogenic effects at lower doses, sedative effects at higher doses, and disrupting sensorimotor gating. The accumulation of MXP in brain tissue is likely to contribute to acute intoxication in humans, potentially leading to negative experiences. Our findings highlight the potentially dangerous effects of recreational MXP use and underscore the risks of inducing serious adverse health outcomes.
Citace poskytuje Crossref.org